PAR2 blockade reverses osimertinib resistance in non-small-cell lung cancer cells via attenuating ERK-mediated EMT and PD-L1 expression
- 1 January 2022
- journal article
- research article
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Molecular Cell Research
- Vol. 1869 (1) , 119144
Abstract
No abstract availableKeywords
Funding Information
- Science and Technology Department of Sichuan Province
- National Natural Science Foundation of China
This publication has 41 references indexed in Scilit:
- Change in PD-L1 Expression After Acquiring Resistance to Gefitinib in EGFR-Mutant Non–Small-Cell Lung CancerClinical Lung Cancer, 2016
- Distinct EMT programs control normal mammary stem cells and tumour-initiating cellsNature, 2015
- PD-1–PD-L1 axis: efficient checkpoint blockade against cancerNature Reviews Clinical Oncology, 2014
- Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppressionNature Communications, 2014
- Growth and survival of lung cancer cells: regulation by kallikrein-related peptidase 6 via activation of proteinase-activated receptor 2 and the epidermal growth factor receptorBiological Chemistry, 2014
- Activation of Proteinase-Activated Receptor 2 Prevents Apoptosis of Lung Cancer CellsCancer Investigation, 2013
- Reactivation of ERK Signaling Causes Resistance to EGFR Kinase InhibitorsCancer Discovery, 2012
- Interdicting protease-activated receptor-2-driven inflammation with cell-penetrating pepducinsProceedings of the National Academy of Sciences, 2011
- Signal Transduction for Proteinase-Activated Receptor-2-Triggered Prostaglandin E2 Formation in Human Lung Epithelial CellsThe Journal of Pharmacology and Experimental Therapeutics, 2005
- Protease-activated Receptor 2 in Colon CancerJournal of Biological Chemistry, 2004